¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"central inhibitory state"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • prolactin inhibitory factor
    ÇÁ·Î¶ôƾºÐºñ¾ïÁ¦ÀÎÀÚ
  • peripheral inhibitory field
    ¸»ÃʾïÁ¦¿µ¿ª
  • reticular inhibitory area
    ±×¹°Ã¼¾ïÁ¦ºÎÀ§
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
  • anxiety state
    ºÒ¾È»óÅÂ
  • acute confusional state
    ±Þ¼ºÈ¥µ·»óÅÂ
  • basal state
    ±âÃÊ»óÅÂ
  • clouded state
    ȥŹ»óÅÂ
  • condensed state
    ÃàÇÕ»óÅÂ
  • correlated state
    »ó°ü»óÅÂ
  • critical state
    ÀÓ°è»óÅÂ
  • carrier state
    º¸±Õ»óÅÂ
  • dynamic state
    ¿ªµ¿»óÅÂ
  • dormant state
    Àẹ»óÅÂ, ÀáÀç»óÅÂ, ÈÞ¸é»óÅÂ
  • dreamy state
    ¸ù·Õ»óÅÂ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relaxation state
    À̿ϻóÅÂ
  • saturation state
    Æ÷È­»óÅÂ
  • steady state
    Ç×Á¤»óÅÂ
  • vegetative state
    ½Ä¹°»óÅÂ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitory interneuron
    ¾ïÁ¦»çÀ̽Ű漼Æ÷
  • inhibitory synapse
    ¾ïÁ¦¿¬Á¢
  • inhibitory transmitter
    ¾ïÁ¦Àü´Þ¹°
  • inhibitory postsynaptic potential
    ¾ïÁ¦½Ã³ÀÈÄÀüÀ§, ¾ïÁ¦¿¬Á¢ÈÄÀüÀ§
  • central amaurosis
    ÁßÃßÈæ¾Ï½Ã
  • central aphasia
    ÁßÃß¾ð¾î»ó½ÇÁõ
  • central artery
    Á߽ɵ¿¸Æ
  • central ataxia
    ÁßÃßÁ¶È­¿îµ¿ºÒ´É
  • central attachment
    Á߽ɺÎÂø
  • central retinal artery
    ¸Á¸·Á߽ɵ¿¸Æ
  • central visual acuity
    Á߽ɽ÷Â
  • central
    Áß½É-, ÁßÃß-
  • central callus
    Á߽ɾֹú»À
  • central canal
    Á߽ɰü
  • central cataract
    Á߽ɹ鳻Àå
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitory action
    ÀúÁöÀÛ¿ë(îÁò­íÂéÄ).
  • inhibitory autacoid
    ¾ïÁ¦¿À¿ÀŸÄÚÀ̵å.
  • inhibitory concentration, minimum (MIC)
    ¾ïÁ¦ÃÖ¼Ò³óµµ
  • inhibitory effect
    ¾ïÁ¦È¿°ú(åäð¤ Íý).
  • inhibitory effect
    ¾ïÁ¦È¿°ú.
  • inhibitory enzyme
    ÀúÇØÈ¿¼Ò.
  • inhibitory hormone
    ¾ïÁ¦(åäð¤)È£¸£¸ó.
  • inhibitory junctional potential
    ¾ïÁ¦¼º Á¢ÇÕºÎÀü¾Ð(ïÈùêݬï³äâ).
  • inhibitory nerve
    ¾ïÁ¦½Å°æ(åäð¤ãêÌè).
  • inhibitory nerve
    ¾ïÁ¦½Å°æ.
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄ Àü¾Ð
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory postsynaptic potential = IPSP
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory synapse
    ¾ïÁ¦¼º(åäð¤àõ) ½Ã³³½º.
  • inhibitory synapse
    ¾ïÁ¦¼º ½Ã³³½º.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitory postsynaptic potential = IPSP
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory synapse
    ¾ïÁ¦¼º ½Ã³³½º.
  • inhibitory synapse
    ¾ïÁ¦¼º(åäð¤àõ) ½Ã³³½º.
  • inhibitory transmitter
    ¾ïÁ¦¼º Àü´Þ¹°Áú.
  • inhibitory zone
    ¾ïÁ¦¹üÀ§(åäð¤ÛôêÌ).
  • luteotrop(h)ic hormone inhibitory factor =LTHIF
    ȲüÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ(üÜô÷ô§Ð½¡­åäð¤ì×í­).
  • lymphocyte inhibitory factor (LIF)
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • macrophage migration inhibitory factor
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ.
  • migration inhibitory factor =MIF
    ´ë½Ä¼¼Æ÷À¯ÁÖÀúÁöÀÎÀÚ(ÓÞãÝá¬øàë´ñËîÁ ò­ì×í­).
  • migratory inhibitory factor
    À̵¿¼º ¾ïÁ¦ÀÎÀÚ
  • minimal inhibitory concentration
    ÃÖÀú¹ßÀ°ÀúÁö³óµµ(õÌî¸Û¡ëÀðæò­ÒØöô).
  • minimum inhibitory concentration
    ÃÖ¼Ò¹ßÀ°ÀúÁö³óµµ(õÌá³Û¡ëÀîÁò­ÒØöô).
  • minimum inhibitory concentration
    ÃÖ¼Ò¾ïÁ¦³óµµ
  • minimum inhibitory concentration
    ÃÖ¼Ò¹ßÀ°ÀúÁö³óµµ(̧ËÛËÑËôËøÌ¤ËÀ̬).
  • minimum inhibitory dose
    ÃÖ¼Ò¾ïÁ¦·®(¡­åäð¤åÖ).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Central
    Áß½É, ÁßÃß
    [¿¾ ¿ë¾î] Áß½É, ÁßÃß
  • Central sulcus
    Á߽ɰí¶û
    [¿¾ ¿ë¾î] Á߽ɱ¸
  • Artery of central sulcus
    Á߽ɰí¶ûµ¿¸Æ
    [¿¾ ¿ë¾î] Á߽ɱ¸µ¿¸Æ
  • Central canal
    Á߽ɰü
    [¿¾ ¿ë¾î] Á߽ɰü
  • Harversian canal [Central canal]
    Á߽ɰü
    [¿¾ ¿ë¾î] °ñ¿øÁ߽ɰü
  • Central zone
    Á߽ɱ¸¿ª
    [¿¾ ¿ë¾î] Á߽ɴë
  • Central tendon
    Á߽ɳÎÈûÁÙ
    [¿¾ ¿ë¾î] °ÇÁß½É
  • Central tegmental tract
    Áß½ÉµÚÆÇ·Î
    [¿¾ ¿ë¾î] Áß½ÉÇǰ³·Î
  • Central lacteal
    Á߽ɸ²ÇÁ°ü
    [¿¾ ¿ë¾î] Áß½ÉÀӯİü
  • Central lymph nodes
    Á߽ɸ²ÇÁÀý
    [¿¾ ¿ë¾î] Áß½ÉÀÓÆÄÀý
  • Central heterochromatic part
    Á߽ɹ¶Ä£¿°»öÁúºÎºÐ
    [¿¾ ¿ë¾î] Áß½ÉÀÌ¿°»öÁúºÎ
  • Central microtubule
    Á߽ɹ̼¼°ü
    [¿¾ ¿ë¾î] Á߽ɹ̼Ұü
  • Central part
    Á߽ɺκÐ
    [¿¾ ¿ë¾î] Á߽ɺÎ
  • Central attachment
    Á߽ɺÎÂø
    [¿¾ ¿ë¾î] Á߽ɺÎÂø
  • Central insertion
    Á߽ɺÎÂø
    [¿¾ ¿ë¾î] Á߽ɺÎÂø
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • haploid state
    ÀϹèü »óÅÂ(ìéÛÃô÷»óÅÂ)
  • heteroploid state
    À̼ö »óÅÂ(ì¶â¦ßÒ÷¾)
  • hyperploid state
    °ú¹è¼ö »óÅÂ(ΦÛÃâ¦ßÒ÷¾)
  • hypoploid state
    Àú¹è¼ö »óÅÂ(î¸ÛÃâ¦ßÒ÷¾)
  • metastable state
    ÁؾÈÁ¤ »óÅÂ(ñ×äÌïÒßÒ÷¾)
  • oxidation state
    »êÈ­»óÅÂ(ß«ûùßÒ÷¾)
  • polyploid state
    ´Ù¹èü»óÅÂ(ÒýÛÃô÷ßÒ÷¾)
  • postabsorptive state
    Èí¼öÈÄ »óÅÂ(ýåâ¥ý­ßÒ÷¾)
  • pre-steady-state kinetics
    ÀüÁ¤À¯»óÅÂ(îñïÒë§ßÒ÷¾) ¿ªÇÐ(ÕôùÊ)
  • singlet state
    ´ÜÇ×»óÅÂ(Ó¤ú£ßÒ÷¾)
  • standard state
    Ç¥ÁØ »óÅÂ(øöñÞßÒ÷¾)
  • state function
    »óÅ ÇÔ¼ö(ßÒ÷¾ùÞâ¦)
  • state of a system
    ½Ã½ºÅÛ »óÅÂ(ßÒ÷¾)
  • stationary state
    Á¤Áö »óÅ (ïÎò­ßÒ÷¾)
  • stationary-state approximation
    Á¤Áö »óÅÂ(ïÎò­ßÒ÷¾) ¾î¸²¼À
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • FAST(Fourier acquisition in the steady state) sequence
    Ç×Á¤»óÅ¿¡¼­ÀÇ Fourierȹµæ¿¬¼â
  • Fourier acquisition in the steady state [=FAST]
    Ç×Á¤»óÅ¿¡¼­ÀÇ Fourierȹµæ
  • partial saturation state
    ºÎºÐÆ÷È­»óÅÂ
  • relaxation state
    À̿ϻóÅÂ
  • saturation state
    Æ÷È­»óÅÂ
  • SSFP [=steady state free precession]
    Ç×Á¤»óÅÂÀÚÀ¯¼¼Â÷
  • steady state
    Ç×Á¤»óÅÂ
  • steady state coherent sequence
    Ç×Á¤»óŰáÁý¿¬¼â
  • steady state free precession [=SSFP]
    Ç×Á¤»óÅÂÀÚÀ¯¼¼Â÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CTT cefotetan; central tegmental tract; central transmission time; compressed tablet triturate; computer...
CVO central vein occlusion; central venous oxygen; Chief Veterinary Officer; credentialing verification ...
GIP   1) Giant cell Interstitial Pneumonia
  2) Gastric Inhibitory (Poly)Peptide
IPSP Inhibitory Post-Synaptic Potential; ¾ïÁ¦¼º ½Ã³À½ºÈÄ ÀüÀ§
MIC Minimum(Minimal) Inhibitory Concentration
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
GMS Geriatric Mental State Schedule
GRASS Gradient-recalled acquisition in the steady state
MLSS Maximal lactate steady state
MMS Mini Mental State
MMSE Mini Mental State Exam
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • macrophage migration inhibitory factor
    ´ë½Ä ¼¼Æ÷ À¯ÁÖ ÀúÁö ÀÎÀÚ, °Å½Ä ¼¼Æ÷ À¯ÁÖ ¾ïÁ¦ ÀÎÀÚ
  • migration inhibitory factor test
    À¯ÁÖ ÀúÁö ÀÎÀÚ ½ÃÇè
    ƯÀÌ Ç׿ø¿¡ ¹ÝÀÀÇÏ¿© ¸²ÇÁ±¸°¡ MIF¸¦ »ý¼ºÇÏ´Â µ¥ ´ëÇÑ »ýüÀÇ ½ÃÇè¹ýÀ¸·Î ¼¼Æ÷ ¸Å°³ ¸é¿ªÀ» Æò°¡ÇÏ´Â µ¥ »ç¿ëÇÑ´Ù. ÀϺΠ¸é¿ª °áÇÌ Áúº´, Áï DiGeorge ÁõÈıº, Wiskott-Aldrich ÁõÈıº, Hodgkin º´¿¡¼­´Â MIF°¡ »ý¼ºµÇÁö ¾Ê´Â´Ù.
  • minimum inhibitory dose
    ÃÖ¼Ò ¾ïÁ¦·®
  • peripheral inhibitory field
    ¸»ÃÊ ¾ïÁ¦¾ß
  • presynaptic inhibitory action
    ½Ã³³½ºÀü ¾ïÁ¦ ÀÛ¿ë
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º ¾ïÁ¦ ÀÎÀÚ
  • active state
    Ȱµ¿ »óÅÂ
    ±ÙÀ°ÀÌ ¼öÃàÇÒ ¶§, ¼öÃà¿ä¼Ò ÀÚü¿¡ ÀϾ°í ÀÖ´Â ¿ªÇÐÀû »óÅÂÀÌ´Ù. ±ÙÀ° ÀÚü¿¡ ź¼º¿ä¼Ò°¡ Á¸ÀçÇϹǷΠ´Ü¼øÇÑ ¼öÃà°î¼±ÀÇ ±â·ÏÀ¸·Î Ȱµ¿»óȲÀ» ¾Ë ¼ö ¾ø´Ù. ¼öÃà¿ä¼Ò´Â ±ÙÀ°ÀÌ ÀڱصǸé Áï½Ã Ȱµ¿»óŰ¡ µÇ°í, Á¦2, Á¦3ÀÇ ÀÚ±ØÀÌ °¡ÇØÁ®µµ ÀÌ È°µ¿»óÅ´ °­È­µÇÁö ¾Ê°í ´Ü¼øÈ÷ Áö¼Ó½Ã°£ÀÌ ¿¬ÀåµÉ »ÓÀÌ´Ù.
  • allergic state
    ¾Ë·¹¸£±â »óÅÂ
    Ven Pirquet´Â Ç׿ø ¹°Áú¿¡ ´ëÇÏ¿© º¯È­ÇÑ ¹ÝÀÀ ´É·ÂÀ» °¡Áö°í ÀÖ´Â »óŸ¦ ¾Ë·¹¸£±â »óŶó°í ºÒ·¶À¸³ª ÇöÀç´Â °íÃÊ¿­À̳ª õ½Ä µîÀÇ ¾ÆÅäÇǼº Áúȯ°ú °°ÀÌ ¾Ë·¹¸£±â°¡ ¿øÀÎÀÌ µÇ´Â Áúȯ¿¡ ´ëÇØ¼­¸¸ »ç¿ëµÈ´Ù.
  • basal state
    ±âÃÊ »óÅÂ
  • correlated state
    »ó°ü »óÅÂ
  • critical state
    ÀÓ°è »óÅÂ
  • dental care councils of state dental association
    ÁÖ Ä¡°úÀÇ»çÇùȸ
  • emotional state
    Á¤¼­ »óÅÂ
  • epileptic state
    °£Áú »óÅÂ
  • equation of state
    »óÅ ¹æÁ¤½Ä
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
leukocyte migration-inhibitory factors Protein factor(s) released by sensitised lymphocytes (and possibly other cells) that inhibit the movement of leukocytes, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the leukocyte migration capillary tube technique (lmct) and the leukocyte migration agarose technique (lmat).
(12 Dec 1998)
absent state The saemiconscious state associated with an epileptic attack.
Synonym: absent state.
(05 Mar 2000)
activated state <chemistry, radiobiology> An atom or nucleus which possesses more energy than its ground state energy.
(16 Dec 1997)
acute confusional state <psychiatry> A condition of severe confusion or rapid change in brain function. This often occurs as the result of a mental illness or physical illness.
Symptoms include lethargy, agitation, confusion, disorientation and delirium.
(27 Sep 1997)
anxiety tension state A milder form of an anxiety disorder.
See: anxiety disorders.
(05 Mar 2000)
apallic state Diffuse, bilateral cerebral cortical degeneration caused by head injury, anoxia, or encephalitis, a state of persistent unresponsiveness, such as akinetic mutism, caused by brain damage.
See: vegetative.
Synonym: apallic syndrome, apallic.
(05 Mar 2000)
carrier state A condition in which a human who is not himself sick harbors an infective organism which may cause disease in those to whom it is transmitted.
(12 Dec 1998)
refractory state Subnormal excitability immediately following a response to previous excitation; the state is divided into absolute and relative phases.
(05 Mar 2000)
perfect state In fungi, that portion of the life cycle in which spores are formed after nuclear fusion.
(05 Mar 2000)
mental state <clinical sign, psychiatry> A finding on physical examination that may refer to any number of abnormal changes in baseline mental functioning.
Milder examples include mood changes, irritability, personality changes, depression or blunted affect. Advanced changes include confusion, lethargy, sleepiness, hallucinations, unresponsiveness and coma.
(27 Sep 1997)
ground state <chemistry, radiobiology> The state of a nucleus, atom or molecule at its lowest energy. All other states are excited.
(16 Dec 1997)
persistent vegetative state A persistent loss of upper cortical function that may follow acute (e.g., infections, toxins, trauma or vascular) events or chronic (e.g., degenerative) events. The patient is bedridden and nutritional support is completely passive, either parenteral or via nasogastric tube. The patient does not require respiratory support or circulatory assistance for survival and is in a state of chronic wakefulness without awareness which may be accompanied by spontaneous eye opening, grunts or screams, brief smiles, sporadic movement of facial muscles and limbs. While the eyes blink upon stimulation, they do not do so in response to visual threats. Some patients chew or clamp their teeth. Urinary and faecal incontinence is universal.
(12 Dec 1998)
convulsive state <disease, neurology> The paroxysmal transient disturbances of brain function that may be manifested as episodic impairment or loss of consciousness, abnormal motor phenomena, psychic or sensory disturbances or perturbation of the autonomic nervous system.
Symptoms are due to paroxysmal disturbance of the electrical activity of the brain. On the basis of origin, epilepsy is idiopathic (cryptogenic, essential, genetic) or symptomatic (acquired, organic). On the basis of clinical and electroencephalographic phenomenon, four subdivisions are recognised:
1. Grand mal epilepsy (major epilepsy, haut mal epilepsy) subgroups: generalised, focal (localised), jacksonian (rolandic)
2. Petit mal epilepsy
3. Psychomotor epilepsy (temporal lobe epilepsy, psychic, psychic equivalent or variant) subgroups: psychomotor proper (tonic with adversive or torsion movements or masticatory phenomena), automatic (with amnesia) and sensory (hallucinations or dream states or d‚j. Vu)
4. Autonomic epilepsy (diencephalic), with flushing, pallor, tachycardia, hypertension, perspiration or other visceral symptoms.
Synonym: epilepsia.
Origin: Gr. Epilepsia = seizure
(14 May 1997)
post-ictal state A period of confusion, lethargy and deep breathing that may last for 15 minutes to several hours after the cessation of a generalised seizure.
(27 Sep 1997)
post-steady state Any period of time, particularly in an enzyme-catalyzed reaction, after the steady-state interval; e.g., when the rate of product formation is declining in an enzyme-catalyzed reaction.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • central casting
    (¿µÈ­ ÃÍ¿µ¼ÒÀÇ)¹è¿ªºÎ
  • central city
    ´ëµµ½Ã±ÇÀÇ Á߽ɵµ½Ã;ÇÙµµ½Ã
  • central control station
    Áß¾ÓÁ¦¾î±¹
  • central dogma
    ¼¾Æ®·²µµ±×¸Ó(À¯ÀüÁ¤º¸ÀÇ ºÐÀÚ»ý¹°ÇÐÀÇ ±âº» ¿ø¸®)
  • central government
    Áß¾Ó Á¤ºÎ(Áö¹æ Á¤ºÎ¿¡ ´ëÇÑ)
  • central heating
    Áß¾Ó ³­¹æ(ÀåÄ¡)
  • central nervous system
    ÁßÃß ½Å°æ°è
  • central processing unit
    Áß¾Ó Ã³¸® ÀåÄ¡(CPU)
  • central reserve(reservation)
    MEDIAN STRIP
  • state
    »óÅÂ,±¹°¡,ÁÖ,½ÅºÐ,ÁöÀ§
  • state rights
    ÁÖÀÇ ±Ç¸®
  • state' attorney
    ÁÖ´ëÇ¥ÀÇ º¯È£»ç
  • state's attorney
    ÁÖ´ëÇ¥ÀÇ º¯È£»ç
  • Badger State
    ¹Ì±¹ÀÇ ÁÖ
  • Bear State
    arkansasÁÖÀÇ µý À̸§
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á